Halogenated pyrimidine sensitization of low dose rate irradiation in human malignant glioma.

Published

Journal Article

PURPOSE: To determine the potential advantage of combining halogenated pyrimidine radiosensitization and continuous low dose rate irradiation in human malignant glioma. METHODS AND MATERIALS: An established glioma line (U-251) was incubated with 5-bromo-2-doxyuridine (BrdUrd) at clinically achievable concentrations at three dose rates of interest--100 cGy/min (typical of external beam therapy), 43 cGy/hr (typical of temporary afterloaded implants), and 12 cGy/hr (typical of permanent implants). RESULTS: After exposure to 1 microM BrdUrd, the greatest enhancement ratio was seen at the 12 cGy/hr dose rate, implying a BrdUrd induced inverse dose rate effect independent of a G2M block. Under these conditions, the mean inactivation dose after 1 microM BrdUrd exposure was equivalent for 100 cGy/min and 12 cGy/hr. CONCLUSION: These results support the use of halopyrimidines as sensitizers of temporary afterloaded and permanent implants.

Full Text

Duke Authors

Cited Authors

  • McLaughlin, PW; Mancini, WR; Stetson, PL; Greenberg, HS; Nguyen, N; Seabury, H; Heidorn, DB; Lawrence, TS

Published Date

  • July 15, 1993

Published In

Volume / Issue

  • 26 / 4

Start / End Page

  • 637 - 642

PubMed ID

  • 8330994

Pubmed Central ID

  • 8330994

International Standard Serial Number (ISSN)

  • 0360-3016

Digital Object Identifier (DOI)

  • 10.1016/0360-3016(93)90281-y

Language

  • eng

Conference Location

  • United States